GSA Capital Partners’s Relmada Therapeutics RLMD Stock Holding History

GSA Capital Partners’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$136K	Buy	+19,566	New	+$92.6K	0.01%	1527
2025 Q1	–	Sell	-124,773	Closed	-$65K	–	2010
2024 Q4	$65K	Buy	124,773 +16,361	+15%	+$39.9K	﹤0.01%	1524
2024 Q3	$351K	Buy	108,412 +297	+0.3%	+$962	0.03%	1144
2024 Q2	$324K	Buy	108,115 +4,794	+5%	+$17.3K	0.02%	1229
2024 Q1	$480K	Sell	103,321 -81,252	-44%	-$392K	0.04%	908
2023 Q4	$764K	Sell	184,573 -10,842	-6%	-$32.1K	0.06%	545
2023 Q3	$586K	Sell	195,415 -76,109	-28%	-$226K	0.05%	697
2023 Q2	$668K	Buy	271,524 +208,926	+334%	+$578K	0.07%	556
2023 Q1	$141K	Sell	62,598 -59,992	-49%	-$207K	0.01%	1315
2022 Q4	$428K	Buy	+122,590	New	+$1.08M	0.05%	698
2022 Q1	–	Sell	-17,429	Closed	-$393K	–	1773
2021 Q4	$393K	Buy	+17,429	New	+$388K	0.05%	753

Other funds holding RLMD

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

SSC

Spruce Street Capital New York $416M AUM

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GSA Capital Partners's RLMD Position: Q1 2026 in Review

GSA Capital Partners opened a new position in Relmada Therapeutics (RLMD) in Q1 2026: 19,566 shares worth $136K. The stake represents 0.01% of the portfolio and ranks #1527 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in RLMD as recently as Q4 2024.

GSA Capital Partners first reported a position in RLMD in Q4 2021 and has held it in 11 quarters since. The position peaked at $764K in Q4 2023. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

GSA Capital Partners held 19,566 shares of Relmada Therapeutics worth $136K as of Q1 2026.
Relmada Therapeutics was a new GSA Capital Partners position in Q1 2026.
Relmada Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1527 holding.
GSA Capital Partners first reported a position in Relmada Therapeutics in Q4 2021 and has held it in 11 quarters since.
GSA Capital Partners's Relmada Therapeutics position peaked at $764K in Q4 2023.
103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.